Vectormune FP ILT

RSS

Fowlpox and avian infectious laryngotracheitis vaccine (live, recombinant)

Authorised
This medicine is authorised for use in the European Union.

Overview

Vectormune FP ILT is a veterinary vaccine used in chickens to reduce skin lesions due to fowlpox (FP) and to reduce the clinical signs and tracheal (windpipe) lesions due to avian infectious laryngotracheitis (ILT).

Vectormune FP ILT contains the active substance live fowlpox virus which has been modified to produce two specific proteins from the avian infectious laryngotracheitis virus.

This EPAR was last updated on 10/09/2021

Authorisation details

Product details
Name
Vectormune FP ILT
Agency product number
EMEA/V/C/005482
Active substance
recombinant fowlpox virus expressing the membrane fusion protein and the encapsidation protein of avian infectious laryngotracheitis virus, live
International non-proprietary name (INN) or common name
Fowlpox and avian infectious laryngotracheitis vaccine (live, recombinant)
Species
Chicken
Publication details
Marketing-authorisation holder
CEVA-Phylaxia Co. Ltd.
Date of issue of marketing authorisation valid throughout the European Union
09/12/2020
Contact address

Szállás u. 5.
1107 Budapest
Hungary

Product information

Vectormune FP ILT - EMEA/V/C/005482 -

Contents

Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.

Pharmacotherapeutic group

Not yet assigned

Therapeutic indication

For active immunisation of chickens from 8 weeks of age in order to reduce the skin lesions due to fowlpox and to reduce the clinical signs and tracheal lesions due to avian infectious laryngotracheitis. 

Assessment history

Related content

How useful was this page?

Add your rating